Skip to main content
SpringerLink
Log in

An understanding of the pharmacokinetics of HMG-CoA reductase inhibitors should help reduce the incidence of serious drug interactions

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table

References

  1. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41 (5): 343–70.

    Article  PubMed  CAS  Google Scholar 

  2. Martin J, Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? [published erratum appears in Drug Saf 2003; 26 (12): 893]. Drug Saf 2003; 26 (1): 13–21.

    Article  PubMed  CAS  Google Scholar 

  3. British National Formulary No. 45 [online]. Available from URL: http://www.bnf.org [Accessed 2003 Aug 8]

  4. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22 (6): 441–57.

    Article  PubMed  CAS  Google Scholar 

  5. Kantola T, Neuvonen P. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 387–402

    Article  Google Scholar 

  6. Lilja J, Neuvonen P. Grapefruit juice — simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 64: 477–83

    Article  PubMed  CAS  Google Scholar 

  7. Ameer B, Weintraub R. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997; 33: 103–21

    Article  PubMed  CAS  Google Scholar 

  8. Blum C. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am J Cardiol 1994; 73: D3–11

    Article  Google Scholar 

  9. Furberg C, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiavasc Med 2001; 2: 205–7

    Article  Google Scholar 

  10. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301 (3): 1042–51.

    Article  PubMed  CAS  Google Scholar 

  11. Vacek JL, Dittmeier G, Chiarelli T, et al. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol 1995; 76: 182–4

    Article  PubMed  CAS  Google Scholar 

  12. Gardner SF, Schneider EF, Granberry MC, et al. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy 1996; 16: 419–23

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

An understanding of the pharmacokinetics of HMG-CoA reductase inhibitors should help reduce the incidence of serious drug interactions. Drugs Ther. Perspect 19, 21–24 (2003). https://doi.org/10.2165/00042310-200319120-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200319120-00007

Keywords

Search

Navigation